Athersys Inc jumps as respiratory disease treatment shows promise

Athersys

06/08/2021 13:29

** Shares of cell therapy developer  ATHX.O  jumps 15%
premarket, stock to open at over three-month high of $1.77
    ** Co says its partner in Japan, HEALIOS K.K., released data
that showed co's MultiStem cell therapy met main goal in
patients with acute respiratory distress syndrome (ARDS) in an
open-label study  urn:newsml:reuters.com:*:nFWN2PD0XD
    ** Healios says main goal of ventilator-free days and
secondary goal of 90-day mortality were met in both
pneumonia-induced ARDS patients as well as in COVID-induced ARDS
patients 
    ** Shares set for their best day since beginning of the year
    ** ATHX down 12% YTD, as of last close 

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))